DK641787A - Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for aids, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet - Google Patents

Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for aids, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet

Info

Publication number
DK641787A
DK641787A DK641787A DK641787A DK641787A DK 641787 A DK641787 A DK 641787A DK 641787 A DK641787 A DK 641787A DK 641787 A DK641787 A DK 641787A DK 641787 A DK641787 A DK 641787A
Authority
DK
Denmark
Prior art keywords
glycoprotein
virus
virus vector
aids
responsible
Prior art date
Application number
DK641787A
Other languages
English (en)
Other versions
DK175613B1 (da
DK641787D0 (da
Inventor
Marie-Paule Kieny
Guy Rautmann
Jean-Pierre Lecocq
Simon Wain-Hobson
Marc Girard
Luc Montagnier
Original Assignee
Transgene Sa
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26225146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK641787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8605043A external-priority patent/FR2596771B1/fr
Application filed by Transgene Sa, Pasteur Institut filed Critical Transgene Sa
Publication of DK641787A publication Critical patent/DK641787A/da
Publication of DK641787D0 publication Critical patent/DK641787D0/da
Application granted granted Critical
Publication of DK175613B1 publication Critical patent/DK175613B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK198706417A 1986-04-08 1987-12-07 Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for AIDS, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet DK175613B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR8605043 1986-04-08
FR8605043A FR2596771B1 (fr) 1986-04-08 1986-04-08 Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
FR8615106 1986-10-29
FR8615106A FR2606029B2 (fr) 1986-04-08 1986-10-29 Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
FR8700116 1987-01-08
PCT/FR1987/000116 WO1987006260A1 (fr) 1986-04-08 1987-04-08 Vecteur viral, codant pour une glycoproteine du virus responsable du s.i.d.a., vaccin et anticorps

Publications (3)

Publication Number Publication Date
DK641787A true DK641787A (da) 1987-12-07
DK641787D0 DK641787D0 (da) 1987-12-07
DK175613B1 DK175613B1 (da) 2004-12-27

Family

ID=26225146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198706417A DK175613B1 (da) 1986-04-08 1987-12-07 Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for AIDS, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet

Country Status (12)

Country Link
EP (1) EP0245136B1 (da)
JP (3) JP2719917B2 (da)
KR (1) KR960001819B1 (da)
AT (1) ATE103328T1 (da)
AU (1) AU604696B2 (da)
CA (1) CA1341353C (da)
DE (1) DE3789400T2 (da)
DK (1) DK175613B1 (da)
ES (1) ES2052589T3 (da)
FR (1) FR2606029B2 (da)
PT (1) PT84640B (da)
WO (1) WO1987006260A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0897987B1 (en) * 1989-10-24 2001-02-28 Chiron Corporation Secretion of human protein linked to gamma interferon signal peptide
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6228608B1 (en) * 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
GB9215233D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
CN1304580C (zh) * 2004-07-09 2007-03-14 楼伟 重组表达人获得性免疫缺陷病毒I型的表面糖蛋白gp160
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
IL82104A0 (en) * 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins

Also Published As

Publication number Publication date
ES2052589T3 (es) 1994-07-16
KR880701283A (ko) 1988-07-26
DK175613B1 (da) 2004-12-27
DE3789400D1 (de) 1994-04-28
FR2606029B2 (fr) 1989-02-03
JP2719917B2 (ja) 1998-02-25
EP0245136B1 (fr) 1994-03-23
AU7234987A (en) 1987-11-09
KR960001819B1 (en) 1996-02-05
PT84640B (pt) 1989-11-30
FR2606029A2 (fr) 1988-05-06
JPH1059868A (ja) 1998-03-03
EP0245136A1 (fr) 1987-11-11
ATE103328T1 (de) 1994-04-15
AU604696B2 (en) 1991-01-03
PT84640A (fr) 1987-05-01
JP2743164B2 (ja) 1998-04-22
DE3789400T2 (de) 1994-09-01
DK641787D0 (da) 1987-12-07
JPH08224090A (ja) 1996-09-03
CA1341353C (fr) 2002-04-02
WO1987006260A1 (fr) 1987-10-22
JPH01500161A (ja) 1989-01-26

Similar Documents

Publication Publication Date Title
DK641787D0 (da) Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for aids, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet
AU1225088A (en) Peptides having immunological properties 2-hiv-2
EP0278940A3 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
DE68929467D1 (de) HIV-2 Varianten
ATE230798T1 (de) Rekombinanter herpes simplex gb-gd-impfstoff
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
AU580059B2 (en) Vaccine against rabies and preparation process thereof
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
DK498387D0 (da) Virus-dna-sekvens
AU2520692A (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus
OA09653A (en) Rubella peptides
DK631387D0 (da) Virusvektor
DK0414035T3 (da) Gibbonabe-leukæmi-virusreceptor
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
WO1988007080A3 (en) Transgenic animal cells resistant to viral infection
CA2141670A1 (en) Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus